Kontinuierliche Doppelaspirationstechnik mit Zoom-System für Schlaganfall (ADAPT 2 0)
Klinische Bewertung der kontinuierlichen Dual-Aspirationstechnik mit dem Zoom-System für Schlaganfall (ADAPT 2.0)
This study is designed to evaluate the effectiveness, safety and clinical performance of ADAPT 2.0, first-line aspiration neurothrombectomy with Zoom System with Continuous Dual Aspiration Technique (CDAT).
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Pojai Phattanagosai
- Telefonnummer: 650-740-7703
- E-Mail: pphattanagosai@Imperativecare.com
Studieren Sie die Kontaktsicherung
- Name: Emma Pham
- Telefonnummer: 408-421-7684
- E-Mail: epham@imperativecare.com
Studienorte
-
-
Alabama
-
Huntsville, Alabama, Vereinigte Staaten, 35801
- Rekrutierung
- Huntsville Hospital
-
Kontakt:
- Farrar Hickey
-
Hauptermittler:
- R. Dana Tomalty, MD
-
-
California
-
Walnut Creek, California, Vereinigte Staaten, 94598
- Rekrutierung
- John Muir Health
-
Hauptermittler:
- Benjamin Yim, MD
-
Kontakt:
- Melenie Aaron
-
-
Florida
-
Tampa, Florida, Vereinigte Staaten, 33606
- Rekrutierung
- University of South Florida
-
Hauptermittler:
- Maxim Mokin, MD
-
Kontakt:
- Kilaun Robinson
-
-
Georgia
-
Marietta, Georgia, Vereinigte Staaten, 30060
- Rekrutierung
- Wellstar Kennestone Hospital
-
Kontakt:
- Autumn Lee
-
Hauptermittler:
- Ahmad Khaldi, MD
-
-
Louisiana
-
Lafayette, Louisiana, Vereinigte Staaten, 70503
- Rekrutierung
- Ochsner Clinic Foundation (Lafayette)
-
Hauptermittler:
- Shail Thanki, MD
-
New Orleans, Louisiana, Vereinigte Staaten, 70121
- Rekrutierung
- Ochsner Clinic Foundation
-
Hauptermittler:
- James Milburn, MD
-
Kontakt:
- Jessica Henry
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21201
- Rekrutierung
- University of Maryland
-
Hauptermittler:
- Jacob Cherian, MD
-
Kontakt:
- Katie Henry
-
-
Minnesota
-
Minneapolis, Minnesota, Vereinigte Staaten, 55407
- Rekrutierung
- Allina Health
-
Kontakt:
- Emeryth Beloy
-
Hauptermittler:
- Collin Torok, MD
-
-
New York
-
Albany, New York, Vereinigte Staaten, 12208
- Rekrutierung
- Albany Medical College
-
Hauptermittler:
- Alexandra Paul, MD
-
Kontakt:
- Chelsey Large
-
Buffalo, New York, Vereinigte Staaten, 14203
- Rekrutierung
- University at Buffalo Neurosurgery
-
Hauptermittler:
- Jason Davies, MD
-
Kontakt:
- Ellen Carl
-
New York, New York, Vereinigte Staaten, 10065
- Rekrutierung
- Weill Cornell Medicine
-
Kontakt:
- Hanah Hwang
-
Hauptermittler:
- Amol Mehta, MD
-
New York, New York, Vereinigte Staaten, 10029
- Rekrutierung
- Icahn School of Medicine at Mount Sinai
-
Kontakt:
- Kevin Buttet
-
Hauptermittler:
- Michael T Caton, MD
-
Syracuse, New York, Vereinigte Staaten, 13210
- Rekrutierung
- SUNY Upstate Medical Center
-
Kontakt:
- Saptarshi Prachi
-
Hauptermittler:
- Haydn Hoffman, MD
-
The Bronx, New York, Vereinigte Staaten, 10467
- Rekrutierung
- Montefiore Medical Center
-
Kontakt:
- Genesis Liriano
-
Hauptermittler:
- Amanda Baker, MD
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 45220
- Rekrutierung
- TriHealth Good Samaritan Hospital
-
Hauptermittler:
- Andrew Ringer, MD
-
Kontakt:
- Mehnaaz Ali
-
Columbus, Ohio, Vereinigte Staaten, 43221
- Rekrutierung
- The Ohio State University Wexner Medical Center
-
Hauptermittler:
- Patrick Youssef, MD
-
Hauptermittler:
- Shahid Nimjee, MD
-
Kontakt:
- Edward Belizaire
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- Rekrutierung
- University of Oklahoma, Health Science Center
-
Hauptermittler:
- Hakeem Shakir, MD
-
Kontakt:
- Sanaa Hameed
-
-
South Carolina
-
Greenville, South Carolina, Vereinigte Staaten, 29605
- Rekrutierung
- Prisma Health - Upstate
-
Kontakt:
- Shawn Manos
-
Hauptermittler:
- Jan Vargas Machaj, MD
-
-
Tennessee
-
Knoxville, Tennessee, Vereinigte Staaten, 37902
- Rekrutierung
- Fort Sanders Regional Medical Center
-
Kontakt:
- Cameron Carter
-
Hauptermittler:
- Robert Hixson, MD
-
Memphis, Tennessee, Vereinigte Staaten, 38120
- Rekrutierung
- Semmes Murphey Foundation
-
Hauptermittler:
- Lucas Elijovich, MD
-
Kontakt:
- Wendell Barnett
-
-
Texas
-
Kingwood, Texas, Vereinigte Staaten, 77339
- Rekrutierung
- HCA Houston Healthcare Kingwood
-
Hauptermittler:
- Mohamad Ezzeldin, MD
-
Kontakt:
- Swathi Potla
-
San Antonio, Texas, Vereinigte Staaten, 78229
- Rekrutierung
- Methodist Healthcare System of San Antonio
-
Kontakt:
- Samantha Franklin
-
Hauptermittler:
- Lee Birnbaum, MD
-
San Antonio, Texas, Vereinigte Staaten, 78229
- Rekrutierung
- University of Texas Science Health Center at San Antonio
-
Hauptermittler:
- Justin Mascitelli, MD
-
Kontakt:
- Athena Lazaris-Conner
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84112
- Rekrutierung
- University of Utah
-
Kontakt:
- Andrew Grandemange
-
Hauptermittler:
- Robert Rennert, MD
-
-
Virginia
-
Falls Church, Virginia, Vereinigte Staaten, 22042
- Rekrutierung
- Inova Fairfax Medical Campus
-
Kontakt:
- Lauren Monroe
-
Hauptermittler:
- James McEachern, MD
-
-
Washington
-
Spokane, Washington, Vereinigte Staaten, 99204
- Rekrutierung
- Providence Sacred Heart Medical Center and Children's Hospital
-
Kontakt:
- Kyle Kramer
-
Hauptermittler:
- Christopher Zylak, MD
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Adult subjects with acute ischemic stroke secondary to large vessel occlusion (LVO) meeting the study eligibility criteria and providing written informed consent.
Beschreibung
Inclusion Criteria:
- Subject is ≥ 18 years of age
- Subject or legally authorized representative has provided written informed consent prior to any study-specific procedures and no later than 72 hours after the index procedure
- Pre-stroke mRS 0-2
- Subject is undergoing or has undergone an aspiration thrombectomy using the Zoom System with Continuous Dual Aspiration Technique (CDAT) as the first line device within its intended use
Exclusion Criteria:
- Subjects with a life expectancy of less than 6 months
- Female subject who is known to be pregnant at time of admission
- Any intracranial hemorrhage in the qualifying head CT or MRI
- Presence of tandem internal carotid artery occlusion, multiple occlusion locations (e.g., cavernous ICA and M1, separate M2 occlusions, etc.), or occlusions in multiple territories (e.g., MCA and ACA, bilateral, etc.).
- In the opinion of the Investigator, the patient is not a suitable candidate for intervention with the Zoom System
- Subject is currently enrolled in or planned to be enrolled in any concurrent interventional study that may impact the safety or performance data collected in this study
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
ADAPT 2.0: Zoom System with Continuous Dual Aspiration Technique (CDAT)
The Zoom System is intended to be used as the first-line device and utilized within the FDA-cleared indications for use, consistent with the approved labeling and intended anatomical targets. |
Aspiration neurothrombectomy using Zoom System with Continuous Dual Aspiration Technique (CDAT)
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Proportion of patients achieving modified Thrombolysis in Cerebral Infarction (mTICI) score of ≥2c at the end of procedure, as adjudicated by independent core-lab
Zeitfenster: End of procedure
|
mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
End of procedure
|
|
Rate of Embolization to New Territory (ENT) on final angiography at the end of the procedure by investigator assessment
Zeitfenster: End of procedure
|
Embolization to New Territory (ENT), defined as the presence of new occlusions on final angiography that occur in vascular territories remote from those effected by index stroke, as assessed by the investigator |
End of procedure
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Time to achieve mTICI≥2c, defined as groin puncture to investigator assessment for mTICI≥2c
Zeitfenster: Intraprocedural
|
The time from groin puncture to mTICI (modified treatment in cerebral infarction) score ≥ 2c using study device and technique. mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
Intraprocedural
|
|
Proportion of cases with clot ingestion, as evidenced by clot captured within the Zoom POD
Zeitfenster: Intraprocedural
|
Proportion of cases with clot ingestion, as evidenced by clot captured within at least one of the Zoom PODs |
Intraprocedural
|
|
Proportion of cases with clot captured within the Zoom POD connected to the outer aspiration catheter
Zeitfenster: Intraprocedural
|
Proportion of cases with clot ingestion, as evidenced by clot captured within the outer Zoom PODs |
Intraprocedural
|
|
Rate of rescue therapy
Zeitfenster: Intraprocedural
|
Proportion of cases with rescue therapy, defined as unplanned use of another manufacturer's thrombectomy device, angioplasty, or stenting within the target vessel territory to achieve mTICI≥2c. |
Intraprocedural
|
|
Rate of functional independence (mRS 0-2) at 90 days
Zeitfenster: 90 days post-procedure
|
Proportion of patients achieving mRS (modified Rankin Scale) ≤2 at 90 days mRS range: 0 to 6; The mRS scale ranges from 0 (no symptoms) to 5 (severe disability), with an additional category of 6 for death; higher score means worse outcome |
90 days post-procedure
|
|
Proportion of patients achieving First Pass Effect (FPE) mTICI ≥2c as adjudicated by independent core-lab
Zeitfenster: Intraprocedural
|
Proportion of cases achieving First Pass Effect (FPE), defined as mTICI ≥2c after the first pass with the study device and technique as adjudicated by independent core-lab mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
Intraprocedural
|
|
Rate of symptomatic intracranial hemorrhage (sICH), as confirmed by imaging and independently adjudicated by medical monitor, at the 24-hour post-procedure
Zeitfenster: 24-hour post-procedure
|
Independently adjudicated rate of symptomatic intracranial hemorrhage (sICH) defined as any apparently extravascular blood in the brain or within the cranium confirmed by imaging that is associated with clinical deterioration as defined by an increase of four or more points in the NIHSS at 24 hours compared to the baseline assessment, or that led to death, and was judged to be the predominant cause of a neurologic deterioration or death, per ECASS III criteria |
24-hour post-procedure
|
|
90-day all-cause mortality
Zeitfenster: 90 days post-procedure
|
Rate of all-cause mortality through 90 days post-procedure |
90 days post-procedure
|
|
Rate of device-related Serious Adverse Events, independently adjudicated medical monitor
Zeitfenster: Intraprocedural
|
Independently adjudicated rate of Serious Adverse Events related to study device |
Intraprocedural
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: David Fiorella, MD, Stony Brook University
- Hauptermittler: Shahram Majidi, MD, Icahn School of Medicine at Mount Sinai
- Hauptermittler: Justin Masciteli, MD, The University of Texas Health Science Center at San Antonio
- Hauptermittler: Maxim Mokin, MD, University of South Florida
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Zerebrovaskuläre Erkrankungen
- Erkrankungen des Gehirns
- Erkrankungen des zentralen Nervensystems
- Erkrankungen des Nervensystems
- Gefäßerkrankungen
- Herz-Kreislauf-Erkrankungen
- Ischämischer Schlaganfall
- Streicheln
- Chirurgische Eingriffe, operativ
- Gefäßchirurgische Verfahren
- Kardiovaskuläre chirurgische Eingriffe
- Thrombektomie
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- ICI-2025-003
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .